Marieke van Son

100 CHAPTER 5 REFERENCES 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians 2019; 69(1): 7-34. 2. Cancer Research UK. Prostate cancer sta- tistics. https://www.cancerresearchuk . org/health-professional/cancer-statistics/ statistics-by-cancer-type/prostate-can- cer#heading-Four(accessed11June2019). 3. Zumsteg ZS, Spratt DE, Romesser PB, et al. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. Eur Urol 2015; 67(6): 1009-16. 4. Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B, Zelefsky MJ. Long-term sur- vival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2013; 85(3): 686-92. 5. Routman DM, Funk RK, Stish BJ, et al. Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Out- comes in 974 patients. Brachytherapy 2019; 18(1): 1-7. 6. Zumsteg ZS, Spratt DE, Romesser PB, et al. Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer. The Journal of urology 2015; 194(6): 1624-30. 7. Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR, Cancer of the Prostate Strategic Urological Research E. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and out- comes. Cancer 2008; 112(2): 307-14. 8. Elishmereni M, Kheifetz Y, Shukrun I, et al. Predicting time to castration re- sistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model inte- grating patient data. The Prostate 2016; 76(1): 48-57. 9. Lee RJ, Smith MR. Hormone Therapy for Prostate Cancer. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Bio- therapy: Principles and Practice. 5th ed: Wolters Kluwer: Lippincott Williams & Wilkins; 2011. 10. Philippou Y, Parker RA, Volanis D, Gnanapragasam VJ. Comparative Onco- logic and Toxicity Outcomes of Salvage Radical Prostatectomy Versus Non- surgical Therapies for Radiorecurrent Prostate Cancer: A Meta-Regression Analysis. European urology focus 2016; 2(2): 158-71. 11. Maenhout M, Peters M, van Vulpen M, et al. Focal MRI-Guided Salvage High- Dose-Rate Brachytherapy in Patients With Radiorecurrent Prostate Cancer. Technology in cancer research & treat- ment 2017; 16(6): 1194-201. 12. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. Journal of clinical oncology : of- ficial journal of the American Society of Clinical Oncology 1998; 16(1): 139-44. 13. van Son M, Peters M, Moerland M, Kerk- meijer L, Lagendijk J, van der Voort van Zyp J. Focal Salvage Treatment of Radio- recurrent Prostate Cancer: A Narrative Review of Current Strategies and Future Perspectives. Cancers 2018; 10(12). 14. Murgic J, Morton G, Loblaw A, et al. Focal Salvage High Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer After Primary Radiation Therapy Failure: Results From a Prospective Clinical Trial. Int J Radiat Oncol Biol Phys 2018; 102(3): 561-7.